Covidien CFO Charles Dockendorff plans to retire at the end of 2014, leaving a vacancy in a role he's filled for 25 years.
Covidien (NYSE:COV) said it's searching for a new CFO after Charles Dockendorff announced his plans to retire from the company at the end of 2014.
Dockendorff has been with the company since 1989, serving in a variety of finance-related roles. He was named CFO of Covidien predecessor Tyco Healthcare in 1995, helping lead the company to $10 billion in sales in 2007.
Covidien beats Wall Street's Q1 expectations despite a 19% profit dip, and the company touts a patent infringement win against Johnson & Johnson subsidiary Ethicon Endo-Surgery.
Massachusetts medical device maker Covidien opens a Center of Innovation in China, planning 3 more centers this year in emerging markets.
True to its promises, Covidien (NYSE:COV) is making big strides in emerging markets, today announcing the opening of its 1st Center of Innovation in India.
Covidien touts 510(k) clearance for its LigaSure Maryland jaw open/laparoscopic sealer/divider.
Covidien (NYSE:COV) won 510(k) clearance from the FDA for its LigaSure Maryland jaw open/laparoscopic sealer/divider, the company announced this week.
Covidien said it's pulling the plug on its OneShot renal denervation device, citing the slow development of the hypertension market.
Covidien (NYSE:COV) said it plans to wind down its OneShot renal denervation program, largely due to "slower than expected development of the renal denervation market," meaning the end for a U.S. clinical trial of the high blood pressure device.
In case you couldn't make it to sunny San Francisco, here are some of the best medical device stories that came out of the J.P. Morgan Healthcare conference this week.
Covidien hands its Confluent Surgical product line over to Integra LifeSciences in a deal worth up to $260 million.